Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PEPD | P12955 | 1/20 | 0.39 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 11/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20330222 | 0.83 | TSHR (0.46) | TSHRPEPDXPNPEP1CHRNB2CHRNA4 | |
| SCHEMBL20330221 | 0.76 | TSHR (0.40) | TSHRPEPDXPNPEP1CHRNB2CHRNA4 | |
| SCHEMBL10281126 | 0.75 | PIN1 (0.47) | PEPDXPNPEP1PIN1DPP4DPP8 | |
| SCHEMBL10281125 | 0.75 | PIN1 (0.47) | PEPDXPNPEP1PIN1DPP4DPP8 | |
| SCHEMBL25510762 | 0.73 | DPP4 (0.41) | DPP4DPP8DPP7 | |
| SCHEMBL3782725 | 0.72 | MMP2 (0.65) | PEPDXPNPEP1PIN1DPP4MMP2 | |
| SCHEMBL3785989 | 0.72 | MMP2 (0.65) | PEPDXPNPEP1PIN1DPP4MMP2 | |
| SCHEMBL3789843 | 0.72 | MMP2 (0.65) | PEPDXPNPEP1PIN1DPP4MMP2 | |
| SCHEMBL3780617 | 0.72 | MMP2 (0.65) | PEPDXPNPEP1PIN1DPP4MMP2 | |
| SCHEMBL25505409 | 0.70 | TSHR (0.43) | TSHRDPP4DPP8DPP7DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144051-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144051-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | TSHR 4707/4885PEPD 3310/4885XPNPEP1 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.